Literature DB >> 22384454

Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases.

J Langhorst1, J Boone.   

Abstract

The diagnosis and management of inflammatory bowel diseases (IBD), i.e., Crohn's disease and ulcerative colitis, still present a number of challenges. The fecal biomarker lactoferrin has been shown to be useful in the diagnosis and management of these diseases. This review includes a discussion of the current literature on lactoferrin as a biomarker of intestinal disease, detection of disease activity in IBD, comparison of lactoferrin to endoscopy and histology, lactoferrin measurement in pediatric IBD and lactoferrin as a biomarker for monitoring medical treatment in IBD. Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22384454     DOI： 10.1358/dot.2012.48.2.1732555

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN： 1699-3993            Impact factor:   2.245


  10 in total

1.  Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study.

Authors:  F Barbut; C Gouot; N Lapidus; L Suzon; R Syed-Zaidi; V Lalande; C Eckert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-12       Impact factor: 3.267

2.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

Review 3.  The Lactoferrin Phenomenon-A Miracle Molecule.

Authors:  Paweł Kowalczyk; Katarzyna Kaczyńska; Patrycja Kleczkowska; Iwona Bukowska-Ośko; Karol Kramkowski; Dorota Sulejczak
Journal:  Molecules       Date:  2022-05-04       Impact factor: 4.927

Review 4.  Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: where are we now in the era of the next generation proteomics?

Authors:  Jong-Min Park; Na Young Han; Young-Min Han; Mi Kyung Chung; Hoo Keun Lee; Kwang Hyun Ko; Eun-Hee Kim; Ki Baik Hahm
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease.

Authors:  Dario Sorrentino; Vu Q Nguyen; Kim Love
Journal:  Dig Dis       Date:  2021-02-25       Impact factor: 2.404

6.  Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection.

Authors:  Lucía Pastor; Jost Langhorst; Dorit Schröder; Aina Casellas; Andreas Ruffer; Jorge Carrillo; Victor Urrea; Sergio Massora; Inacio Mandomando; Julià Blanco; Denise Naniche
Journal:  PLoS One       Date:  2019-06-11       Impact factor: 3.240

7.  Proteases from Entamoeba spp. and Pathogenic Free-Living Amoebae as Virulence Factors.

Authors:  Jesús Serrano-Luna; Carolina Piña-Vázquez; Magda Reyes-López; Guillermo Ortiz-Estrada; Mireya de la Garza
Journal:  J Trop Med       Date:  2013-02-07

8.  Adaptive HIV-specific B cell-derived humoral immune defenses of the intestinal mucosa in children exposed to HIV via breast-feeding.

Authors:  Sandrine Moussa; Mohammad-Ali Jenabian; Jean Chrysostome Gody; Josiane Léal; Gérard Grésenguet; Alain Le Faou; Laurent Bélec
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

9.  Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection.

Authors:  J H Boone; J R DiPersio; M J Tan; S-J Salstrom; K N Wickham; R J Carman; H R Totty; R E Albert; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-18       Impact factor: 3.267

10.  Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease.

Authors:  Dario Sorrentino; James M Gray
Journal:  Inflamm Bowel Dis       Date:  2021-07-27       Impact factor: 5.325
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.